Sino Biopharmaceutical Limited
1177
Xếp hạng trong cổ phiếu
#1753
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Giá cổ phiếu
$0.69080164
Vốn hóa thị trường
$12.30B
Thay đổi (1 ngày)
2.86%
Thay đổi (1 năm)
-27.78%
Quốc gia
HK
Giao dịch Sino Biopharmaceutical Limited (1177)
Danh mục
Healthcare
Lịch sử lợi suất cổ tức của Sino Biopharmaceutical Limited (1177)
Lợi suất cổ tức (TTM) của Sino Biopharmaceutical Limited (mã cổ phiếu: 1177) tại thời điểm 2023-12-31 là: 0.89%
Lợi suất cổ tức trung bình trong 5 năm qua: 1.65%
Lợi suất cổ tức trung bình trong 5 năm qua: 1.65%
Lịch sử lợi suất cổ tức của Sino Biopharmaceutical Limited (1177) từ 2000 đến 2026
Lợi suất cổ tức vào cuối mỗi năm (TTM)
| Năm | Lợi suất cổ tức | Thay đổi |
|---|---|---|
| 2026 (TTM) | 2.29% | -35.31% |
| 2024 | 3.54% | 297.75% |
| 2023 | 0.89% | -47.34% |
| 2022 | 1.69% | 50.89% |
| 2021 | 1.12% | 12.00% |
| 2020 | 1.00% | 49.25% |
| 2019 | 0.67% | -47.24% |
| 2018 | 1.27% | 139.62% |
| 2017 | 0.53% | -51.82% |
| 2016 | 1.10% | 92.98% |
| 2015 | 0.57% | -38.04% |
| 2014 | 0.92% | 12.20% |
| 2013 | 0.82% | -24.07% |
| 2012 | 1.08% | -68.79% |
| 2011 | 3.46% | 23.57% |
| 2010 | 2.80% | 83.01% |
| 2009 | 1.53% | -73.25% |
| 2008 | 5.72% | 40.89% |
| 2007 | 4.06% | -15.24% |
| 2006 | 4.79% | -55.40% |
| 2005 | 10.74% | 51.05% |
| 2004 | 7.11% | -15.76% |
| 2003 | 8.44% | -71.44% |
| 2002 | 29.55% | 34.50% |
| 2001 | 21.97% | 88.26% |
| 2000 | 11.67% | 0.00% |
Lợi suất cổ tức (TTM) của các công ty tương tự hoặc đối thủ
| Công ty | Lợi suất cổ tức | Quốc gia |
|---|---|---|
| 1.57% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
